[化疗药物引起的药物反应]

[Drug reactions caused by chemotherapy agents].

作者信息

Ehmann L M, Schrumpf H, Gerber P A, Homey B

机构信息

Hautklinik, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

出版信息

Hautarzt. 2014 May;65(5):443-9. doi: 10.1007/s00105-013-2699-6.

DOI:10.1007/s00105-013-2699-6

PMID:24820802

Abstract

In recent years, several new classes of compounds have successfully been established in the treatment of cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects of these anticancer agents include cutaneous reactions and occur in a time-dependant manner and show class-specific patterns. In this review article, we compare the cutaneous side effects of epidermal growth factor inhibitors (EGFRI), multikinase inhibitors (MKI), BRAF inhibitors (BRAFI), mTor inhibitors (mTorI) and immune checkpoint inhibitors and discuss severity-adapted management strategies.

摘要

近年来，几类新型化合物已成功应用于癌症治疗。它们能选择性抑制紊乱的信号通路或诱导抗肿瘤免疫反应。与传统化疗药物相比，这些新型靶向抗癌药物显示出良好的安全性。这些抗癌药物最重要的副作用包括皮肤反应，其发生具有时间依赖性并呈现出类别特异性模式。在这篇综述文章中，我们比较了表皮生长因子抑制剂（EGFRI）、多激酶抑制剂（MKI）、BRAF抑制剂（BRAFI）、mTor抑制剂（mTorI）和免疫检查点抑制剂的皮肤副作用，并讨论了根据严重程度调整的管理策略。